Information Provided By: 
Fly News Breaks for June 9, 2017
ENDP, EGLT
Jun 9, 2017 | 08:48 EDT
After the FDA requested that Endo (ENDP) remove its Opana ER opioid from the market due to increased risk of abuse using injections, JMP Securities analyst Jason Butler says that Egalet's (EGLT) abuse deterrent opioid alternatives could be boosted by the FDA's increased scrutiny of opioids. The analyst reiterates a $15 price target and Outperform rating on the stock.
News For EGLT;ENDP From the Last 2 Days
There are no results for your query EGLT;ENDP
